NCT01823198 - Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2013

Primary Completion Date

May 10, 2022

Study Completion Date

May 10, 2022

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Erythroid LeukemiaAcute Megakaryoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts Under 20 Percent of Bone Marrow Nucleated CellsBlasts Under 20 Percent of Peripheral Blood White CellsChronic Myelomonocytic LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveTherapy-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic Syndrome

Interventions

BIOLOGICAL

Aldesleukin

Given SC

BIOLOGICAL

Allogeneic CD56-positive CD3-negative Natural Killer Cells

Given IV

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSC transplant

DRUG

Busulfan

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSC transplant

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER